BRPI0813695B8 - compostos de heteroaril piridil e fenil benzenossulfonamidas fundidas, composição, método de modular a função de ccr2, usos dos compostos e forma cristalina - Google Patents
compostos de heteroaril piridil e fenil benzenossulfonamidas fundidas, composição, método de modular a função de ccr2, usos dos compostos e forma cristalinaInfo
- Publication number
- BRPI0813695B8 BRPI0813695B8 BRPI0813695A BRPI0813695A BRPI0813695B8 BR PI0813695 B8 BRPI0813695 B8 BR PI0813695B8 BR PI0813695 A BRPI0813695 A BR PI0813695A BR PI0813695 A BRPI0813695 A BR PI0813695A BR PI0813695 B8 BRPI0813695 B8 BR PI0813695B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- composition
- crystalline form
- fused heteroaryl
- ccr2 function
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- XAUGWFWQVYXATQ-UHFFFAOYSA-N n-phenylbenzenesulfonamide Chemical class C=1C=CC=CC=1S(=O)(=O)NC1=CC=CC=C1 XAUGWFWQVYXATQ-UHFFFAOYSA-N 0.000 title 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 abstract 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 102000004497 CCR2 Receptors Human genes 0.000 abstract 1
- 108010017312 CCR2 Receptors Proteins 0.000 abstract 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94932807P | 2007-07-12 | 2007-07-12 | |
| US60/949,328 | 2007-07-12 | ||
| PCT/US2008/069813 WO2009009740A1 (en) | 2007-07-12 | 2008-07-11 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0813695A2 BRPI0813695A2 (pt) | 2014-12-30 |
| BRPI0813695B1 BRPI0813695B1 (pt) | 2019-02-12 |
| BRPI0813695B8 true BRPI0813695B8 (pt) | 2021-05-25 |
Family
ID=39852363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0813695A BRPI0813695B8 (pt) | 2007-07-12 | 2008-07-11 | compostos de heteroaril piridil e fenil benzenossulfonamidas fundidas, composição, método de modular a função de ccr2, usos dos compostos e forma cristalina |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US7884110B2 (OSRAM) |
| EP (1) | EP2175859B1 (OSRAM) |
| JP (1) | JP5306344B2 (OSRAM) |
| KR (4) | KR101969689B1 (OSRAM) |
| CN (1) | CN101820881B (OSRAM) |
| AT (1) | ATE548039T1 (OSRAM) |
| AU (1) | AU2008275000B2 (OSRAM) |
| BR (1) | BRPI0813695B8 (OSRAM) |
| CA (1) | CA2692761C (OSRAM) |
| DK (1) | DK2175859T3 (OSRAM) |
| ES (1) | ES2383568T3 (OSRAM) |
| IL (1) | IL203258A (OSRAM) |
| PL (1) | PL2175859T3 (OSRAM) |
| PT (1) | PT2175859E (OSRAM) |
| WO (1) | WO2009009740A1 (OSRAM) |
| ZA (1) | ZA201000212B (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US8519135B2 (en) * | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| ES2383568T3 (es) | 2007-07-12 | 2012-06-22 | Chemocentryx, Inc. | Heteroaril piridil y fenil bencenosulfonamidas condensadas como moduladores de CCR2 para el tratamiento de la inflamación |
| JP5917555B2 (ja) | 2010-12-16 | 2016-05-18 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ケモカイン受容体調節因子としてのリン酸誘導体 |
| DK3345899T3 (da) | 2012-03-01 | 2020-05-11 | Allergan Inc | Benzofuran-2-sulfonamidderivater som kemokinreceptormodulatorer |
| ES2708563T3 (es) | 2013-03-12 | 2019-04-10 | Allergan Inc | Derivados de sulfonamida como moduladores de receptores de quimiocinas |
| US20150152080A1 (en) | 2013-12-02 | 2015-06-04 | Allergan, Inc. | Benzothiophene sulfonamides derivatives as chemokine receptor modulators |
| AU2014360743C1 (en) * | 2013-12-02 | 2021-01-28 | Chemocentryx, Inc. | CCR6 compounds |
| CN104860950A (zh) * | 2014-02-24 | 2015-08-26 | 重庆医药工业研究院有限责任公司 | 一种制备4-氯吡咯[2,3-d]并嘧啶的方法 |
| ES2764840T3 (es) | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
| PT3297438T (pt) | 2015-05-21 | 2022-01-25 | Chemocentryx Inc | Moduladores de ccr2 |
| EP3463350B1 (en) * | 2016-06-03 | 2023-09-13 | ChemoCentryx, Inc. | Pyrrolo-pyridines and pyrrolo-pyrimidines for use in treating liver fibrosis |
| US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| JP7083214B2 (ja) * | 2016-06-13 | 2022-06-10 | ケモセントリックス， インコーポレイテッド | 膵がんを治療する方法 |
| IL266751B (en) * | 2016-11-23 | 2022-07-01 | Chemocentryx Inc | Method of treating focal segmental glomerulosclerosis |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| IL273188B2 (en) | 2017-09-25 | 2023-03-01 | Chemocentryx Inc | Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor |
| CN111417389A (zh) * | 2017-10-11 | 2020-07-14 | 坎莫森特里克斯公司 | Ccr2拮抗剂对局灶性节段性肾小球硬化症的治疗 |
| US20190269664A1 (en) * | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| MA50423A (fr) | 2018-01-08 | 2020-08-26 | Chemocentryx Inc | Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2 |
| JP2021534101A (ja) | 2018-08-09 | 2021-12-09 | ヴェルソー セラピューティクス， インコーポレイテッド | Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用 |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN114206338B (zh) | 2019-07-10 | 2025-12-12 | 凯莫森特里克斯股份有限公司 | 作为pd-l1抑制剂的二氢化茚类 |
| CR20220216A (es) | 2019-10-16 | 2023-01-09 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
| PE20221445A1 (es) | 2019-10-16 | 2022-09-21 | Chemocentryx Inc | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| TW202241889A (zh) | 2020-12-23 | 2022-11-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| AU2022388555A1 (en) | 2021-11-09 | 2024-05-02 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3901855A (en) | 1974-08-07 | 1975-08-26 | Us Air Force | Preparation of polybenzimidazoles |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4227437A (en) | 1977-10-11 | 1980-10-14 | Inloes Thomas L | Frequency detecting apparatus |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4403607A (en) | 1980-05-09 | 1983-09-13 | The Regents Of The University Of California | Compatible internal bone fixation plate |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| JPS61113060A (ja) | 1984-11-08 | 1986-05-30 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料 |
| US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
| DE3825041A1 (de) | 1988-07-20 | 1990-02-15 | Schering Ag | Pyrido(3,2-e)(1,2,4)triazolo(1,5-a)pyrimidin- 2-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, pflanzenwachstumsregulierender und fungizider wirkung |
| JPH04364168A (ja) | 1990-08-08 | 1992-12-16 | Taisho Pharmaceut Co Ltd | スルホンアミドピリジン化合物 |
| EP0472053B1 (en) | 1990-08-20 | 1998-06-17 | Eisai Co., Ltd. | Sulfonamide derivatives |
| JPH06145145A (ja) | 1991-12-27 | 1994-05-24 | Ishihara Sangyo Kaisha Ltd | アミノトリフルオロメチルピリジン誘導体又はその塩、それらの製造方法及びそれらを含有するホスホリパーゼａ▲２▼阻害剤、抗炎症剤並びに抗膵炎剤 |
| JPH06135934A (ja) | 1991-12-27 | 1994-05-17 | Ishihara Sangyo Kaisha Ltd | ピリジン誘導体又はその塩を含有するホスホリパーゼ▲ａ２▼阻害剤、抗炎症剤又は抗膵炎剤 |
| US6159686A (en) | 1992-09-14 | 2000-12-12 | Sri International | Up-converting reporters for biological and other assays |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US5571775A (en) | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
| ATE249213T1 (de) | 1996-02-22 | 2003-09-15 | Tularik Inc | Pentafluorobenzensulfonamiden und analoge |
| US5780488A (en) | 1996-04-03 | 1998-07-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| ES2288305T3 (es) | 1996-09-10 | 2008-01-01 | Theodor-Kocher Institute | Receptor de quimiocinas cxcr3, anticuerpos, acidos nucleicos y metodos de uso. |
| ZA9710197B (en) | 1996-11-13 | 1999-05-12 | Dow Agrosciences Llc | N-arylsulfilimine compounds and their use as catalysts in the preparation of n-arylarylsulfonamide compounds |
| US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
| US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| EP0937711A1 (de) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
| JP4327915B2 (ja) | 1998-03-30 | 2009-09-09 | 株式会社デ・ウエスタン・セラピテクス研究所 | スルフォンアミド誘導体 |
| US6251303B1 (en) | 1998-09-18 | 2001-06-26 | Massachusetts Institute Of Technology | Water-soluble fluorescent nanocrystals |
| US6306610B1 (en) | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| US6380206B1 (en) | 1998-11-23 | 2002-04-30 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with 4,5-diaminopyrimidine derivatives |
| JP2000159665A (ja) | 1998-11-27 | 2000-06-13 | Nippon Kayaku Co Ltd | リウマチの予防または治療剤 |
| AUPP796798A0 (en) | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| EP1418175A1 (en) | 1999-06-28 | 2004-05-12 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
| AU2001243158A1 (en) | 2000-02-18 | 2001-08-27 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
| JP2001335714A (ja) | 2000-03-22 | 2001-12-04 | Fuji Photo Film Co Ltd | アゾ色素、その製造方法、インクジェット用インク、インクジェット記録方法 |
| US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
| AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| JP3699910B2 (ja) | 2000-10-31 | 2005-09-28 | 株式会社東芝 | データ伝送装置、データ伝送方法及びプログラム |
| US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
| US7282338B2 (en) | 2001-06-07 | 2007-10-16 | Chemocentryx, Inc. | Cell migration assay |
| EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| JP2005516936A (ja) | 2001-12-18 | 2005-06-09 | アストラゼネカ・アクチエボラーグ | Ｎ−ピラジニル−チエニルスルホンアミドおよびケモカイン媒介疾患の治療におけるそれらの使用 |
| US7119112B2 (en) | 2002-02-28 | 2006-10-10 | Icagen, Inc. | Sulfonamides as potassium channel blockers |
| WO2003079986A2 (en) | 2002-03-18 | 2003-10-02 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
| EP2399903A1 (en) * | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| AU2003245894A1 (en) | 2002-05-28 | 2003-12-12 | Schott Ag | Method and device for blank pressing glass bodies |
| PT1562940E (pt) | 2002-11-18 | 2007-07-23 | Chemocentryx Inc | Sulfonamidas de arilo. |
| US20070021466A1 (en) | 2002-11-18 | 2007-01-25 | Solomon Ungashe | CCR2 inhibitors and methods of use thereof |
| US20060111351A1 (en) | 2002-11-18 | 2006-05-25 | Solomon Ungashe | Aryl sulfonamides |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| EP1575918A2 (en) | 2002-12-19 | 2005-09-21 | Neurogen Corporation | Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
| ES2401079T3 (es) | 2002-12-20 | 2013-04-16 | Amgen Inc. | Moduladores del asma y de la inflamación alérgica |
| WO2004058265A1 (en) | 2002-12-24 | 2004-07-15 | Biofocus Plc | Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors |
| WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
| CA2526385C (en) | 2003-05-29 | 2008-07-22 | Abbott Laboratories | Continuous dosing regimen with abt-751 |
| EP1643960A2 (en) | 2003-07-02 | 2006-04-12 | Merck & Co., Inc. | Arylsulfonamide derivatives |
| GB0322016D0 (en) | 2003-09-19 | 2003-10-22 | Merck Sharp & Dohme | New compounds |
| EP2474532A1 (en) | 2005-01-14 | 2012-07-11 | ChemoCentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| WO2007014054A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| WO2007014008A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| WO2008008394A1 (en) | 2006-07-12 | 2008-01-17 | Transform Pharmaceuticals, Inc. | Tizanidine succinate salt forms and methods of making and using the same |
| US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
| ES2383568T3 (es) * | 2007-07-12 | 2012-06-22 | Chemocentryx, Inc. | Heteroaril piridil y fenil bencenosulfonamidas condensadas como moduladores de CCR2 para el tratamiento de la inflamación |
| US9715915B2 (en) | 2014-10-30 | 2017-07-25 | Samsung Electronics Co., Ltd. | Magneto-resistive devices including a free layer having different magnetic properties during operations |
| US10251888B2 (en) * | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
-
2008
- 2008-07-11 ES ES08781709T patent/ES2383568T3/es active Active
- 2008-07-11 BR BRPI0813695A patent/BRPI0813695B8/pt active IP Right Grant
- 2008-07-11 EP EP08781709A patent/EP2175859B1/en active Active
- 2008-07-11 AU AU2008275000A patent/AU2008275000B2/en active Active
- 2008-07-11 KR KR1020187010175A patent/KR101969689B1/ko active Active
- 2008-07-11 WO PCT/US2008/069813 patent/WO2009009740A1/en not_active Ceased
- 2008-07-11 DK DK08781709.4T patent/DK2175859T3/da active
- 2008-07-11 CA CA2692761A patent/CA2692761C/en active Active
- 2008-07-11 KR KR1020167010696A patent/KR101790908B1/ko active Active
- 2008-07-11 JP JP2010516274A patent/JP5306344B2/ja active Active
- 2008-07-11 US US12/171,782 patent/US7884110B2/en active Active
- 2008-07-11 PL PL08781709T patent/PL2175859T3/pl unknown
- 2008-07-11 CN CN2008801077713A patent/CN101820881B/zh active Active
- 2008-07-11 PT PT08781709T patent/PT2175859E/pt unknown
- 2008-07-11 KR KR1020107002541A patent/KR101617050B1/ko active Active
- 2008-07-11 KR KR1020177030097A patent/KR101849560B1/ko active Active
- 2008-07-11 AT AT08781709T patent/ATE548039T1/de active
-
2010
- 2010-01-12 IL IL203258A patent/IL203258A/en active IP Right Grant
- 2010-01-12 ZA ZA2010/00212A patent/ZA201000212B/en unknown
- 2010-12-22 US US12/976,768 patent/US8546408B2/en active Active
-
2013
- 2013-10-01 US US14/043,602 patent/US9394307B2/en active Active
-
2016
- 2016-06-28 US US15/195,777 patent/US9745312B2/en active Active
-
2017
- 2017-08-04 US US15/669,410 patent/US10208050B2/en active Active
-
2019
- 2019-01-11 US US16/246,181 patent/US10899765B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0813695B8 (pt) | compostos de heteroaril piridil e fenil benzenossulfonamidas fundidas, composição, método de modular a função de ccr2, usos dos compostos e forma cristalina | |
| WO2008008431A3 (en) | Heteroaryl sulfonamides and ccr2/ccr9 | |
| MX2007008474A (es) | Sulfonamidas de heteroarilo y ccr2. | |
| WO2008008374A3 (en) | Ccr2 inhibitors and methods of use thereof | |
| ATE496905T1 (de) | Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose | |
| DK2046762T3 (da) | Triazolphenylbenzensulfonamider | |
| EA201000615A1 (ru) | Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы) | |
| DE602007006835D1 (de) | Substituierte pyridonverbindungen und anwendungsverfahren | |
| ZA200503986B (en) | Aryl sulfonamides | |
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| CA2865714C (en) | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists | |
| DK3357922T3 (da) | 2-((5-(1-(3-(methylsulfonyl)propyl)piperidin-4-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8h)-on-derivater og relaterede forbindelser som cdk4-inhibitorer til behandling af tumorer | |
| EP2155203A4 (en) | Azaindazole compounds and methods of use | |
| IL195514A (en) | Converted Pyridyl Compounds | |
| NO20090282L (no) | Syklopropylaminderivater som histamin H3 reseptormodulatorer | |
| NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
| NO20090312L (no) | Quinolinonderivater og deres farmasoytiske sammensetninger | |
| ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
| WO2007034278A3 (en) | Fused imidazole derivatives as c3a receptor antagonists | |
| ECSP077307A (es) | Derivados piridínicos de indolin-2-ona, su preparación y su aplicación en terapéutica | |
| WO2005075420A3 (en) | Pyrrolidine derivatives acting as ccr3-receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/02/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |